SpyGlass Pharma (SGP) Cash & Equivalents (2024 - 2026)
SpyGlass Pharma (SGP) posted quarterly Cash & Equivalents of $96.4 million for Q4 2025, up 492.32% year-over-year from $16.3 million in Q4 2024, and up 492.32% quarter-over-quarter from $16.3 million in Q4 2024.
Powered by 
Analysis
SpyGlass Pharma (SGP) Cash & Equivalents (2024 - 2026) Analysis & Trends
SpyGlass Pharma (SGP) has reported Cash & Equivalents for 2 consecutive years, with $96.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash & Equivalents rose 492.32% year-over-year to $96.4 million; the TTM figure through Dec 2025 stood at $96.4 million (up 492.32% YoY), while the FY2025 annual figure was $96.4 million, up 492.32% from the prior year.
- Cash & Equivalents rose to $96.4 million in Q4 2025 per SGP's latest filing, from $16.3 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $96.4 million in Q4 2025 and bottomed at $16.3 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 1.72 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 815.44 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.71 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 811.99 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 544.80 Mn |
| 10 | SpyGlass Pharma | 973.76 Mn | 973.76 Mn | - | 223.14 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 223.14 Mn |
| Dec 31, 2025 | 96.36 Mn |
| Dec 31, 2024 | 16.27 Mn |